WEKO3
アイテム
Therapeutic Effects of a Selective Mineralocorticoid Receptor Blocker as an Additional Combination Antihypertensive Drug in Hypertensive Patients
https://dmu.repo.nii.ac.jp/records/5263
https://dmu.repo.nii.ac.jp/records/5263e94170e4-7531-45b4-b5d2-5bdd0227b29f
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
DKMJ-1-3-Honda-Fulltext (380.4 kB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| タイトル | ||||||||||||||||
| タイトル | Therapeutic Effects of a Selective Mineralocorticoid Receptor Blocker as an Additional Combination Antihypertensive Drug in Hypertensive Patients | |||||||||||||||
| 言語 | ||||||||||||||||
| 言語 | eng | |||||||||||||||
| キーワード | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | hypertension | |||||||||||||||
| キーワード | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | eplerenone | |||||||||||||||
| キーワード | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | mineral corticoid receptor blocker | |||||||||||||||
| キーワード | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | aldosterone | |||||||||||||||
| キーワード | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | albuminuria | |||||||||||||||
| 資源タイプ | ||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||
| 資源タイプ | journal article | |||||||||||||||
| 著者 |
Honda, Takeaki
× Honda, Takeaki
× Ishimitsu, Toshihiko
× Satonaka, Hiroshi
× Iwashima, Yoshio
× Tojo, Akihiro
|
|||||||||||||||
| 著者所属 | ||||||||||||||||
| 値 | Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan | |||||||||||||||
| 著者所属 | ||||||||||||||||
| 値 | Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan | |||||||||||||||
| 著者所属 | ||||||||||||||||
| 値 | Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan | |||||||||||||||
| 著者所属 | ||||||||||||||||
| 値 | Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan | |||||||||||||||
| 著者所属 | ||||||||||||||||
| 値 | Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan | |||||||||||||||
| 書誌情報 |
Dokkyo Medical Journal 巻 1, 号 3, p. 226-234, 発行日 2022-09 |
|||||||||||||||
| 抄録 | ||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||
| 内容記述 | Among the components of renin-angiotensin-aldosterone system, aldosterone facilitates the progression of cardiovascular organ injuries not only by promoting renal tubular Na reabsorption but also by causing oxidative stress, inflammation and cardiovascular tissue hypertrophy and fibrosis. Therefore, mineral corticoid receptor blockers (MRB) supposedly exhibit protective effects against cardiovascular organ injuries in hypertensive patients. In this study, the therapeutic effects of MRB in the combination antihypertensive treatment were examined in hypertensive patients. Fifty mg eplerenone (EPL) was added to 24 hypertensive patients under antihypertensive drug therapy who had not achieved the target blood pressure. The combination was continued for 3 to 4 months and the effects on blood pressure (BP) and laboratory data including renal function and cardiovascular endocrine system were evaluated. After 3-4 months, office BP was lowered from 148/91 to 135/86 mmHg (p<0.001/p=0.002) as well as the home BP (morning 150/86 to 134/81, p = 0.001/p = 0.033; evening 139/80 to 127/74, p = 0.005/p = 0.030). Serum K (4.2 to 4.3 mEq/L, p = 0.014) and creatinine (0.82 to 0.87 mg/dL, P<0.001) increased slightly but significantly. Serum uric acid also increased significantly from 5.8 to 6.4 mg/dL (p = 0.015). However, the indices of glucose metabolism and serum lipids were not affected. In addition to the natural increases in plasma renin and aldosterone, plasma B-type natriuretic peptide (BNP: 23 to 17 pg/mL, p = 0.028) and urinary albumin excretion (111 to 70 mg/gCr, p = 0.009) were significantly decreased. In the combination antihypertensive drug therapy, MRB is expected to reduce cardiac and renal injuries and the influences on glucose and lipid metabolisms seem negligible, however, care should be taken for the development of hyperuricemia and renal dysfunction in addition to hyperkalemia. |
|||||||||||||||
| 記事種別 | ||||||||||||||||
| 値 | Original | |||||||||||||||
| 出版者 | ||||||||||||||||
| 出版者 | Dokkyo Medical Society | |||||||||||||||
| ISSN | ||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||
| 収録物識別子 | 2436-522X | |||||||||||||||
| DOI | ||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||
| 関連識別子 | 10.51040/dkmj.2022-030 | |||||||||||||||
